Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

Balance Sheet

Inspect the capital base behind the business.

Assets

$258.34M

FY 2025 · Annual

-42.4% YoY

Liabilities

$197.33M

FY 2025 · Annual

-66.0% YoY

Equity

$61.01M

FY 2025 · Annual

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents417.2M63.55M102.89M125.99M88.88M
Short-term Investments0128.13M14.86M083.25M
Net Receivables123.02M109.96M260.52M122.33M18.42M
Inventory37.64M38.79M62.61M70.09M3.17M
Other Current Assets10.8M22.92M11.1M11.53M6.23M
Total Current Assets602.32M381.23M475.63M341.58M206.71M
Property, Plant & Equipment (Net)7.81M8.75M5.12M2.84M1.35M
Goodwill943K943K943K00
Intangible Assets2.62M4.99M70.73M53.65M46.24M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets65.64M84.93M77.18M50.47M4.05M
Total Non-current Assets77.01M99.61M153.97M106.95M51.64M
Total Assets679.33M480.85M629.6M448.53M258.34M
Account Payables16.16M11.53M35.22M28.46M9.92M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities22.01M22.61M21.52M33.11M16.07M
Total Current Liabilities165.33M138.69M331.77M282.98M141.88M
Long-term Debt408.28M471.06M473.37M264.93M37.05M
Deferred Tax Liabilities001.1M1.1M1.1M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities750K3.47M11.46M28.23M15.84M
Total Non-current Liabilities416.28M479.57M491.26M297.54M55.45M
Total Liabilities581.61M618.27M823.03M580.52M197.33M
Common Stock7K8K11K12K12K
Retained Earnings(1.05B)(1.34B)(1.58B)(1.55B)(1.38B)
Accumulated OCI(270K)(249K)(248K)(275K)(195K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity97.73M(137.42M)(193.43M)(131.99M)61.01M
Total Debt419.02M480.42M480.84M269.9M40.34M
Net Debt1.83M416.88M377.95M143.92M(48.54M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$115.2M
Short-term Investments$51.8M
Receivables$22.5M
Inventory$4.8M
Other Current$11.7M
Total Current Assets$206.0M
PP&E (Net)$1.1M
Intangible Assets$45.6M
Other Non-current$13.3M
Total Non-current Assets$60.0M
Total Assets$266.0M

Analysis

Selected assets total $266.0M for Latest. The largest visible component is Cash & Equivalents at $115.2M, about 43.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportOct 29, 2026
8-KCurrent reportAug 28, 2026
424B5424B5 filingAug 28, 2026

How much cash does CHRS have?

Coherus Oncology, Inc. (CHRS) reported $88.88M in cash and equivalents in fiscal 2025.

How much debt does CHRS carry?

Coherus Oncology, Inc. (CHRS) reported $40.34M of total debt, with net debt of -$48.54M.